The first total synthesis of Ciliatamides A-C was completed, leading to a revision of the reported stereochemistry from (S,S) to the (R,R) enantiomers. Due to the expedited route, a library of over 50 unnatural ciliatamide analogs was also prepared.
Leishmaniasis is a group of vector-borne diseases, caused by obligate intramacrophage parasites of the genus Leishmania, which is endemic in the tropics.
1,2 The disease may manifest itself as either a cutaneous, a mucosal, a dermal, or as the deadly visceral variant.
3 Second only to malaria, leishmaniasis afflicts more than 12 million people in 88 countries with an annual death toll exceeding 50,000.
1-3 The current treatments for leishmaniasis are the pentavalent antimonials 1 and 2, humatin 3, amphotericin B 4, pentamidine 5, and miltefosine 6 ( Figure 1) ; however, these drugs possess a number of drawbacks including cardiotoxic effects, parenteral administration, long treatment regimens, and high cost. [1] [2] [3] Earlier this year, Nakao and co-workers reported on the isolation of three lipopeptides, Ciliatamides A (7), B (8), and C (9), from the deep sea sponge Aaptos ciliata as the (S,S)-enantiomers (Scheme 1). 4 Importantly, Ciliatamides A and B demonstrated significant antileishmanial activity and,
(1) Pitzer, K. K.; Werbovetz, K. A.; Brendle, J. J.; Scovill, J. P. J. Med. Chem. 1998, 41, 4885-4889. (2 thus, appeared as ideal targets for total synthesis and further biological evaluation as 7-9 are chemically far less complex than current antileishmanials 1-6. [1] [2] [3] [4] The retro-synthesis of 7-9 (Scheme 1) involved cleavage of the two amide bonds to provide the (S)-3-aminoazepan-2-one 10 (for 7 and 8) or the (S)-3-aminopiperid-2-one 11 (for 9), L-N-methyl Phe 12 and either decenoic acid 13 (for 7 and 9) or octanoyl chloride 14 (for 8). Surprisingly, all of the requisite precursors were commercially available.
5
In the event, Boc-L-N-MePhe 15 was coupled to 10 with PS-DCC and HOBt, followed by treatment with HCl in dioxane to deliver the free base 19 in 59% yield for the two steps after ion-exchange chromatography. 19 then underwent a second amide coupling with 13 to afford 7, or with 14 to afford 8 in 56 and 58% yields, respectively. Following the same scheme (Scheme 2), 5 but substituting (S)-3-aminopiperid-2-one 10 for 11, provided Ciliatamide C (9) in 44% yield over the three steps. The overall yields were lower than anticipated due to the physiochemical properties of 7-9, and poor chromatographic performance of these lipopeptides.
Despite this, the NMR spectra obtained were in complete accord with those reported by Nakao and co-workers; however, the original spectra were recorded under very dilute conditions to minimize conformer populations (see Supporting Information).
4
On the basis of these results, we then explored a solution phase parallel synthesis approach for the synthesis of Ciliatamides A (7) and C (9) employing only polymersupported reagents, scavengers and ion-exchange chromatography to avoid either normal or reverse-phase chromatography. 6 This strategy afforded improved results, providing 7 and 9 in overall yields in excess of 75% for the three steps with >95% purity (Scheme 3).
5
Due to the expedited route to 7-9, in parallel, we prepared a 42-member solution phase library of unnatural ciliatamide analogs 20a-n, 21a-n and 22a-n. The library employed three scaffolds 18, 19, and the unnatural (R,S) congener of 19, and a collection of 14 different acid chlorides ( Figure  2 ). All final compounds, including additional copies of 7-9 were purified to >98% by mass-directed preparative HPLC and afforded yields ranging from <5 to 60% for the three steps; however, we obtained sufficient quantities for biological evaluation in every case.
5,7
As we were compiling the final characterization data for 7-9, a discrepancy was noted with respect to the reported optical rotations,
, for the natural products 7-9, respectively. 4 While the 1 H and 13 C NMR spectra of our synthetic 7-9 overlaid with the natural products, the optical rotations were of comparable magnitude, but opposite sign, that is,
) -43 (c ) 0.1, MeOH) for synthetic 7-9, respectively.
5 On the basis of these results, we synthesized the four possible stereoisomers ((S,S), (S,R), (R,S), and (R,R)) of Ciliatamide A and Ciliatamide B, employing the route depicted in Scheme 2, and compared NMR spectra and obtained optical Attempts to prepare the (S,R), (R,S) and (R,R) stereoisomers of Ciliatamide C following the route depicted in Scheme 2 led to significant racemization of the (R)-piperidin-2-one, which was not observed within the Ciliatamide A and B series or the (S)-3-aminopiperdin-2-one 11. Therefore, after several approaches, we developed an alternate route that avoided racemization and afforded pure stereoisomers (Scheme 4). In this instance, the carbodimide coupling in Scheme 2 was replaced with a HATU/collidine system for the coupling of pure (S)-or (R)-piperidin-2-one, 10 and 29, respectively, with either enantiopure Boc-L-N-MePhe 15 or Boc-D-NMePhe 30. The milder acidolysis of the Boc deprotection of 31-33 with 5-7% TFA in CH 2 Cl 2 in an ice bath instead of 10 equiv of HCl was used to deliver isomers 34-36. Finally, a second HATU coupling with decenoic acid provided the remaining stereoisomers of Ciliatamide C 37 (S,R), 38 (R,S), and 39 (R,R). As in the case of Ciliatamides A and B, both NMR spectra and optical rotation ([R] D 20 ) +56 (c ) 0.1, MeOH)) for 39 confirm a stereochemical reassignment of the natural product to the (R,R)-enantiomer.
For Ciliatamides A-C, the optical rotations were positive, and in agreement with the literature report, only when the unnatural D-MePhe was employed. Nakao and co-workers utilized Marfey's analysis 8 to establish the L-configuration of the caprolactams and the MePhe in 7-9; however, the data presented herein suggests that either the reported optical rotations were incorrect, or the stereochemical assignments were incorrect. 4 It is also possible that the natural products, under the forcing acidic conditions of the Marfey's analysis 8 racemized. We have noted that the (R,R)-analogs are prone to acid catalyzed racemization to the (S,S)-enantiomers. Thus, based on our data, we propose a stereochemical revision for Ciliatamides A-C from the (S,S)-7, 8, and 9 to the (R,R)-25, 28, and 39 (Figure 4 ).
We are in the process of developing an antileishmanial assay, which we hope will further validate the stereochemical reassignment of Ciliatamides A-C based on biological activity. However, once a validated assay is in place, we will evaluate all of the unnatural analog ciliatamide libraries in an attempt to develop structure-activity relationships (SAR). We are also in the process of identifying discrete molecular targets, as we have done previously for other marine natural products, 9 for Ciliatamides A-C that might afford a mechanisitic understanding of their antileishmanial activities.
In summary, we have completed the first total synthesis of Ciliatamides A-C, originally reported as as the (S,S)-enantiomers 7-9, employing both traditional organic synthesis and solution phase parallel synthesis. Based on spectral and optical rotation data for all the possible stereoisomers of 7-9, we propose a stereochemical revision for Ciliatamides A-C to the (R,R)-enantiomers 25, 28, and 39 respectively. Due to the expedited route, we also prepared a library of 42 unnatural cilatamide analogs 20a-n, 21a-n, and 22a-n, and when combined with the unnatural stereosiomers, the library exceeds 50 unnatural analogs. Assay development and biological evaluation for both the natural products and the unnatural ciliatamides are in progress and will be reported in due course.
Supporting Information Available:
Experimental procedures, characterization data, and 1 H and 13 C NMR spectra for all new compounds, 7-9, 16-19, 23-28, 31-39, and a cross section of library members 20a-n, 21a-n, and 22a-n. This material is available free of charge via the Internet at http://pubs.acs.org. 
